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The present study was aims to formulate and evaluate transdermal drug delivery for sustained release of 
an anti-hypertensive drug Captopril, it is considered as drug of choice in anti hypertensive therapy and is 
reported for potential administration through transdermal route. The investigation was carried out to 
study the effect of different proportion of ethyl cellulose and PVP a hydrophobic and hydrophilic 
polymer respectively. Transdermal patches were prepared using different combination of the two 
polymers by solvent evaporation technique. Polyvinyl alcohol was used to prepare the backing 
membrane and dibutyl phthalate as a plasticizer. Several Physicochemical parameter like moisture 
content, moisture loss, thickness, film folding endurance, tensile strength, flatness were studied. For all 
the formulations, in vitro drug release was studied using modified diffusion cell. Formulations with 
highest proportion of polyvinyl pyrolidone shows faster release whereas increasing proportion of ethyl 
cellulose produces a prolonged regimen of sustained drug delivery through transdermal route for a 
period of 24 hrs. 
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INTRODUCTION 
Transdermal drug delivery is defined as self contained, 
discrete dosage forms which, when applied to the intact 
skin, deliver the drug through the skin at controlled 
rate to the systemic circulation. Transdermal drug 
delivery system (TDDS) established itself as an 
integral part of novel drug delivery systems.[1] The 
transdermal route of administration is recognized as 
one of the potential route for the local and systemic 
delivery of drugs. In comparison to conventional 
pharmaceutical dosage forms, TDDS offer many 
advantages, such as elimination of first pass 
metabolism, sustained drug delivery, reduced 
frequency of administration, reduced side effects and 
improved patient compliance. The present study is an 
attempt to develop a transdermal system capable of 
delivering the selected anti-hypertensive drug in the 
desired therapeutic concentration for prolong period.[2] 
Captopril, an orally active inhibitor of an angiotensin 
converting enzyme has been widely used for the 
treatment of hypertension and congestive heart failure. 
The drug is considered a drug of choice in 
antihypertensive therapy due to its effectiveness and 
low toxicity. It has a mean half life of 2-3 hrs but 
action lasts for 6-12 hrs. Captopril shows 75% 
bioavailability but presence of food reduces the oral 
absorption by 30-50%. According to a previous 
research, the oxidation rate of captopril in dermal 
homogenate is significantly lower than the intestinal 
homogenate because the oxidative product of captopril, 
a captopril disulfide shows poor absorption from the 
intestine.[3] So, the use of transdermal drug delivery 
system, can reduce the side effects associated with 
captopril. 
 
MATERIAL AND METHODS 
Captopril was purchased from Balaji Drugs. Polyvinyl 
pyrrolidone KǦ30 (PVP KǦ30), Central Drug House (P) 
Ltd. New Delhi; Ethyl cellulose LR (EC), Central Drug 
House (P) Ltd. New Delhi; Di-n-butylphthalate, 
Central Drug House (P) Ltd. New Delhi. 
 Preparation of backing membrane 
A 4% (w/v) solution of polyvinyl alcohol (PVA) in 
distilled water was prepared using mechanical stirrer. 
Then 2 ml of the solution was poured in both side open 
glass moulds, having specific diameter (2.8 cm), one 
side of which is previously covered by aluminum foil. 
It was placed in dryer at 60ºC±2º C for drying over a 
period of 6 hrs. After 6 hrs moulds were removed from 
dryer and air dried for 24 hrs.[4] 
Formulation of transdermal patches 
Matrix type transdermal patches of Captopril were 
prepared by using two polymer compositions, 
containing EC and PVP in different ratios as shown in 
the Table I by solvent evaporation technique in 
cylindrical both side opened glass moulds. Polymers 
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were weighed in requisite ratio and they were then 
dissolved in ethanol as a solvent. Dibutyl phthalate 
30% (w/w) of polymer composition was used as a 
plasticizer. The drug was added 20% (w/w) of the total 
weight of polymer, in the homogeneous dispersion, by 
slow stirring with a magnetic stirrer. The uniform 
dispersion (2 ml each) was casted on the PVA backing 
membrane casted earlier and dried at 40°C for 6 hrs. 
After drying patches were removed from the mold, 
wrapped with aluminium foil and kept in desiccators 
until they were used for further study.  All the patches 
obtained from this composition were smooth, elastic 
and were easily removed from glass moulds.[4] 
 
Evaluation of transdermal patches 
Thickness uniformity:[4] 
Thickness uniformity of the transdermal patches was 
measured with micrometer with least count of 0Ǧ0.01 
mm. The thickness of the patch at five different points 
was measured and the average of five readings with the 
standard deviation was calculated. The procedure was 
followed for all the formulation batches. 
 
Uniformity of weight:[5] 
The patch of size 1x1 cm2 was cut and weight of each 
patch was taken individually, the average weight of the 
patch was calculated. 
 
Percent flatness study:[6] 
Longitudinal strips were cut out from each transdermal 
patch, one from the centre and two from the either side. 
The length of each strip was measured and the 
variation in the length because of nonǦuniform in 
flatness was measured by determining % constriction, 
considering 0% constriction is equivalent to 100 % 
flatness. 
 
Folding endurance:[7] 
The folding endurance was measured manually for the 
prepared patches. The patches were repeatedly folded 
at the same place till it broke. The number of times the 
patches could be folded at the same place without 
breaking gave the exact value of folding endurance.  
 
Drug content uniformity:[8] 
The patches were tested for the content uniformity. The 
patches of size 1 cm2 was cut and placed in a 100 ml 
volumetric flask. The contents were stirred using a 
magnetic bead for 24 hrs to dissolve the patches. 
Subsequent dilutions were made with phosphate buffer 
(pH 7.4). The absorbance of the solution was measured 
against the corresponding blank solution at 212 nm 
using UV-visible spectrophotometer. The experiment 
was repeated three more time to validate the result. 
 
Percent moisture content (%MC):[9] 
The patches were weighed individually and kept in 
desiccators containing 10 gm of calcium chloride as 
desiccant at 37°C for 24 hrs. The patches were 
weighed again and again individually until it showed a 
constant weight. The final weight was noted when 
there was no further change in the weight of individual 
patch. The percentage of moisture content was 
calculated as a difference between initial and final 
weight with respect to final weight. 
%ܯܥ =
ܺ െ ܻ
ܻ
× 100 
  Where, X = initial weight, Y = final weight 
 
Table I: Formulation of drug loaded transdermal patches using EC and PVP 
Formulation 
Code 
Ratio of  
EC: PVP 
Total weight of EC 
& PVP (mg) 
Ethanol 
(ml) 
Plasticizer (% w/w) of 
total polymer 
Drug (% w/w) of 
total polymer      
F1 1:1 500  10  30 20 
F2 1:2 500 10  30 20 
F3 1:3 500  10  30 20 
F4 1:4 500  10  30 20 
F5 2:1 500  10  30 20 
F6 3:1 500 10  30 20 
F7 4:1 500  10  30 20 
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Percentage moisture uptake: [9] 
The patches were weighed accurately and placed in a 
dessicator where a humidity condition of 80-90% RH 
was maintained by using saturated solution of 
potassium chloride. The patches were kept until 
uniform weight is obtained, then taken out and 
weighed. The percentage of moisture uptake was 
calculated as the difference between final and initial 
weight with respect to initial weight. 
%ܯܷ =
ܺ െ ܻ
ܻ
× 100 
   Where, X = initial weight, Y = final weight 
Percentage moisture loss:[5] 
The patches were weighed individually and kept in a 
dessicator containing calcium chloride.  The  final  
weight  was  noted  when  there  was  no  change  in  
the  weight  of individual  patch.  The percentage of 
moisture content was calculated as a difference 
between initial and final weight with respect to final 
weight.  
%ܯܮ =
ܺ െ ܻ
ܻ
× 100 
Where, X = initial weight, Y = final weight 
Water vapour transmission (WVT) rate:[10] 
The study were performed taking vials of equal 
diameter were used as transmission cells. These cells 
were washed thoroughly and dried in an oven. About 1 
g of fused calcium chloride was taken in cells and the 
polymeric patches measuring 1 cm2 area were fixed 
over the brim with the help of an adhesive. The cells 
were weighed accurately and initial weight was 
recorded, and then kept in a closed desecrator 
containing saturated solution of potassium chloride to 
maintain 80-90% RH. The cells were taken out and 
weighed after 24 hrs. The amount  and  rate  of  water  
vapour  transmitted  was  calculated  by  the  difference  
in  weight using the formula.                                                     
ܹܸܶ ݎܽݐ݁ =ܹܮ ܵൗ  
where; W = water vapour transmitted in gm., 
 L = thickness of the transdermal patch in cm.,  
S = exposed surface area in cm2. 
Tensile strength and percentage elongation:[4] 
The tensile strength measurement was made using an 
instrument assembled in the laboratory.  The films 
were fixed individually to the assembly. The required 
weights to break the films were noted. Tensile strength 
was calculated by using the following formula.   
ܶ݁݊ݏ݈݅݁ ݏݐݎ݁݊݃ݐ݄ = ൬
ܾݎ݁ܽ݇ ݂݋ݎܿ݁
ܽ × ܾ
൰× ൬
1 + ܮ
ܫ
൰ 
Where, a, b, L and I are the width, thickness, length 
and elongation of the films.  
 
Table II: Different evaluation parameters of drug loaded transdermal patches 
Formulation 
code 
Thickness 
(mm) 
Weight   
(gm) 
Folding 
endurance 
% MC %MU %ML 
F1 0.2 0.21 >300 3.97 4.48 4.29 
F2 0.18 0.20 >300 4.67 5.82 4.56 
F3 0.19 0.156 >300 5.00 5.97 4.79 
F4 0.15 0.21 >300 5.59 6.36 5.23 
F5 0.21 0.186 >300 4.34 4.51 4.34 
F6 0.21 0.226 >300 3.57 4.12 4.12 
F7 0.19 0.19 >300 3.15 3.58 3.81 
 
RESULTS  
In vitro drug release: [4] 
Modified diffusion cell was used in our studies for in 
vitro drug release. The cell consists of two chambers, 
the donor and the receptor. The donor compartment is 
open at the top and is exposed to the atmosphere. The 
receptor compartment is surrounded by a water jacket 
for maintaining the temperature at 37oC±2oC and is 
provided with a sampling port. The diffusion medium 
was phosphate buffer of pH 7.4, which was stirred with 
magnetic bead (operated by a magnetic stirrer). A 
semi-permeable parchment paper previously soaked 
overnight in 0.1N HCL was placed between the two 
chambers. Diffusion media was stirred to prevent the 
formation of concentrated drug solution just beneath 
the membrane. Samples from the receptor 
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compartment were taken at various intervals of time 
over a period of 24 hrs and the concentration of the 
drug was determined by UV Spectrophotometric 
method using the standard curve at 212 nm. Amount of 
drug diffused at various time intervals was calculated 
and plotted against time. 
  
 Fig I: In vitro cumulative drug release profile of 
formulations F1-F7 using dialysis membrane 
 
DISCUSSION 
In this study transdermal patches of Captopril with 
variable combinations of EC and PVP were prepared 
and prolonged release of the drug through the matrix 
films was demonstrated. The physicochemical 
parameters and the release characteristics were studied 
on the fabricated patches. The thickness, weight 
variation, folding endurance, moisture content and the 
moisture loss were observed (Table II). The thickness 
of the formulated patches FǦ1 to FǦ7 was found to be in 
between 0.15-0.21mm, the folding endurance value of 
all the patches was found satisfactory which ensures 
that patches prepared using plasticizer dibutylphthalate 
(DBP) (30% w/w of polymer) were having optimum 
flexibility and were not brittle. The percent moisture 
content (% w/w) of the formulated patches were found 
in between 3.58-6.36 %   (Table II). In moisture uptake 
study it was observed that moisture uptake value 
increases with gradual increase in concentration of 
hydrophilic polymer PVP. The water vapour 
transmission through the different patch formulations 
prepared taking EC with PVP in different compositions 
showed that the patches were permeable to water and 
showed uniform flatness without any observed 
constriction (Table III). The uniformity in flatness of 
the prepared patches indicates that the formulation by 
solvent casting and solvent evaporation technique is 
reproducible and the formulation can maintain 
satisfactory surface smoothness. The percentage drug 
content of all the formulations was found in between 
95.48-99.69 % (Table III). The drug content of all the 
formulations was found satisfactory. The tensile 
strength of the patches was found in between 210.92-
277.76 gm/cm2 (Table III).  It was observed that with 
increase in concentration of hydrophilic polymers the 
tensile strength of the patches decreases gradually. The 
in vitro drug release from the formulated patches were 
carried out in modified diffusion cell through dialysis 
membrane using 100 ml phosphate buffer (pH 7.4) as 
diffusion media for a period of 24 hrs. It was observed 
that the patches prepared with hydrophilic polymer in a 
higher concentration like formulations F2, F3, F4 
where concentration of PVP is in gradual increasing 
order  the release was very quick and the patches 
releases more than 98 % of the loaded drug far before 
24 hrs and drug release is not in a controlled manner. 
But in case of the patches prepared with hydrophobic 
polymer, EC concentration in a gradual increasing 
order like formulation F5, F6, F7 showed a controlled 
release of the loaded drug over an extended period of 
24 hrs, in this respect formulation F7 showed best 
result amongst all the formulations (Fig I). 
 
CONCLUSION 
In conclusion, in vitro drug release of Captopril from 
its transdermal patches showed that the patches 
containing higher proportion of EC showed suitability 
for a prolonged regimen of sustained drug delivery 
through transdermal route for a period of more than 24 
hrs. The results of the study give a rational guideline 
for formulating a sustained release transdermal 
therapeutic system of Captopril for effective therapy 
and prophylaxis of angina pectoris, cardiac arrhythmia 
and hypertension. 
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Table III: Water vapour transmission rate (WVTR), Percent flatness, Tensile strength, and drug content of 
drug loaded transdermal patches of EC and PVP 
Formulation 
code 
 WVTR      
(gm/cm/h) 
% Flatness Tensile Strength   
(gm/cm2) 
% Elongation %  Drug 
Content 
F1 1.4423x10-4 99.2 236.85 23.8 95.50 
F2 1.9445 x10-4 98 228.34 24.7 96.12 
F3 1.8742 x10-4 97.9 220.89 26.3 96.68 
F4 1.6048 x10-4 97.3 210.92 29.4 95.48 
F5 1.2040 x10-4 98.6 241.59 22.4 98.37 
F6 1.1928 x10-4 99.1 256.26 20.8 96.88 
F7 1.1054 x10-4 100 277.76 19.2 99.69 
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